2025/09/10 by David Schütz, Kirstine Huong Lettorp, Isa Amalie Olofsson +1 · 1 voice
Medicine · #Pregnancy and preeclampsia studies
paper · pdf · doi:10.1016/j.rbmo.2025.105261
openalex publication_date 2025/09/10 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
In order to make clinical recommendations based on uncertain evidence, a systematic review and meta-analysis on the influence of micronutrient supplementation on preclinical and clinical reproductive outcomes was undertaken. PubMed and Scopus were searched until 12 November 2024. Parallel-grouped intervention studies with women undergoing fertility treatment with micronutrient supplementation or addition of micronutrient to in-vitro maturation media were included. The primary outcomes were oocyte maturation and chromosome aneuploidy rates, pregnancy rate, miscarriage rate, and live birth rate. Five of 1810 studies were included. In three clinical studies, 326 women underwent fertility treatment with coenzyme Q10 (CoQ10) or control treatment. CoQ10 increased oocyte retrieval and live birth rates for women diagnosed with poor ovarian response (POR; OR = 2.28), and increased the pregnancy rate for women diagnosed with POR or polycystic ovary syndrome (PCOS) (OR = 2.20 and 13.26, respectively). CoQ10 had no effect on the miscarriage rate. In two in-vitro studies, 127 women donated 241 immature oocytes which were matured with CoQ10 or resveratrol. CoQ10 increased the oocyte maturation rate (OR = 2.73), and decreased oocyte and chromosome aneuploidy rates (OR = 0.31 and 0.57, respectively) for women of advanced maternal age (AMA). Resveratrol had no effect. Women of AMA and women diagnosed with POR or PCOS gained greater benefit from CoQ10 supplementation.